About Alpine Immune Sciences (NASDAQ:ALPN)
Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company's lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-1.12080924855491
Forward P/E Ratio-8.36
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$14.27 per share
Price / Book0.68
Return on Equity-39.40%
Return on Assets-36.05%
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings data on Monday, February, 13th. The biotechnology company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. During the same period in the prior year, the company earned ($0.42) EPS. View Alpine Immune Sciences' Earnings History.
Where is Alpine Immune Sciences' stock going? Where will Alpine Immune Sciences' stock price be in 2018?
2 brokers have issued 12 month target prices for Alpine Immune Sciences' shares. Their predictions range from $17.00 to $17.00. On average, they expect Alpine Immune Sciences' share price to reach $17.00 in the next twelve months. View Analyst Ratings for Alpine Immune Sciences.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Cellular Biomedicine Group (CBMG), Ardelyx (ARDX), MaxCyte (MXCT), Calithera Biosciences (CALA), Tocagen (TOCA), Bellicum Pharmaceuticals (BLCM), Kindred Biosciences (KIN), Zymeworks (ZYME), Chimerix (CMRX), Molecular Templates (MTEM), vTv Therapeutics (VTVT), Faron Pharmaceuticals Oy (FARN), Zafgen (ZFGN), Vital Therapies (VTL), Foamix Pharmaceuticals (FOMX), Minerva Neurosciences (NERV), Ampio Pharmaceuticals (AMPE) and Vascular Biogenics (VBLT).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Howard P. Furst M.D., Chairman of the Board
- R. Michael Carruthers, Interim President, Chief Financial Officer, Secretary
- Janice M. Troha, Chief Operating Officer
- Sherif Gabriel Ph.D., Vice President – Research and Discovery
- Steven Shoemaker M.D., Vice President – Clinical Research and Development, Medical Director
- Robert E. Conway, Independent Director
- Evan Loh M.D., Independent Director
- John R. Moore, Independent Director
- Paul Sekhri, Independent Director
Who owns Alpine Immune Sciences stock?
Alpine Immune Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.49%), Victory Capital Management Inc. (0.37%), Millennium Management LLC (0.13%), Spark Investment Management LLC (0.12%) and Wells Fargo & Company MN (0.08%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.
Who sold Alpine Immune Sciences stock? Who is selling Alpine Immune Sciences stock?
Who bought Alpine Immune Sciences stock? Who is buying Alpine Immune Sciences stock?
Alpine Immune Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Victory Capital Management Inc. and Wells Fargo & Company MN. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.
How do I buy Alpine Immune Sciences stock?
Shares of Alpine Immune Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of Alpine Immune Sciences stock can currently be purchased for approximately $9.70.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $134.65 million. The biotechnology company earns $-31,460,000.00 in net income (profit) each year or ($8.65) on an earnings per share basis. Alpine Immune Sciences employs 15 workers across the globe.
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (ALPN)MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alpine Immune Sciences (NASDAQ:ALPN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Hold||Hold|
|Consensus Rating Score: ||2.50||2.50||2.33||2.43|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$17.00||$17.00||$7.31||$10.88|
|Price Target Upside: ||543.94% upside||543.94% upside||176.99% upside||311.93% upside|
Alpine Immune Sciences (NASDAQ:ALPN) Consensus Price Target History
Alpine Immune Sciences (NASDAQ:ALPN) Analyst Ratings History
(Data available from 2/17/2016 forward)
Alpine Immune Sciences (NASDAQ:ALPN) Earnings History and Estimates Chart
Alpine Immune Sciences (NASDAQ ALPN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3 2017||($0.62)||($0.19)||$0.13 million||View||N/A|
|5/9/2017||Q1 2017||($2.24)||($2.24)||$29.98 million||View||N/A|
Alpine Immune Sciences (NASDAQ:ALPN) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS
Dividend History for Alpine Immune Sciences (NASDAQ:ALPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Alpine Immune Sciences (NASDAQ ALPN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 56.63%
Alpine Immune Sciences (NASDAQ ALPN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/20/2017||Value Fund L P Biotechnology||Insider||Buy||17,806||$2.25||$40,063.50|| |
|6/7/2017||Bvf Partners L P/Il||Major Shareholder||Buy||36,900||$2.28||$84,132.00|| |
|6/7/2017||Value Fund L P Biotechnology||Insider||Buy||72,650||$2.29||$166,368.50|| |
|6/5/2017||Bvf Partners L P/Il||Major Shareholder||Buy||35,750||$2.29||$81,867.50|| |
|5/31/2017||Value Fund L P Biotechnology||Insider||Buy||47,000||$2.27||$106,690.00|| |
|5/19/2017||Value Fund L P Biotechnology||Insider||Buy||78,858||$2.30||$181,373.40|| |
|5/11/2017||Value Fund L P Biotechnology||Insider||Buy||109,034||$2.32||$252,958.88|| |
|5/9/2017||Robert E Conway||Director||Buy||5,000||$2.34||$11,700.00||45,000|| |
|5/8/2017||Robert E Conway||Director||Buy||15,000||$2.28||$34,200.00||60,000|| |
|5/5/2017||Janice Troha||EVP||Buy||10,000||$2.34||$23,400.00||10,000|| |
|5/5/2017||Robert E Conway||Director||Buy||20,000||$2.30||$46,000.00||40,000|| |
|5/4/2017||Robert E Conway||Director||Buy||10,000||$2.26||$22,600.00||20,000|| |
|1/4/2017||David Malcom Rodman||EVP||Sell||6,687||$2.27||$15,179.49||18,055|| |
|12/2/2016||R Michael Carruthers||EVP||Buy||24,000||$2.09||$50,160.00||24,000|| |
|10/4/2016||David Malcom Rodman||EVP||Sell||5,820||$7.96||$46,327.20||18,056|| |
|7/5/2016||David Malcom Rodman||CMO||Sell||5,950||$4.66||$27,727.00||18,055|| |
|6/16/2016||Jon Congleton||CEO||Buy||5,000||$3.87||$19,350.00||20,000|| |
|3/24/2016||Jon Congleton||CEO||Buy||5,000||$4.22||$21,100.00||15,000|| |
|3/22/2016||Jon Congleton||CEO||Buy||5,000||$4.38||$21,900.00||10,000|| |
|12/11/2015||Jon Congleton||CEO||Buy||5,000||$8.10||$40,500.00||5,000|| |
|12/9/2015||Robert E Conway||Director||Buy||10,000||$8.10||$81,000.00||10,000|| |
|6/23/2015||James E Flynn||Insider||Buy||250,000||$14.00||$3,500,000.00|| |
|6/22/2015||Bay Master Investors (C Hawkes||Major Shareholder||Buy||17,200||$14.69||$252,668.00|| |
|6/18/2015||Bay Master Investors (C Hawkes||Major Shareholder||Buy||20,400||$14.47||$295,188.00|| |
|6/17/2015||Global Healthcare Mas Jennison||Major Shareholder||Buy||26,149||$14.00||$366,086.00|| |
Alpine Immune Sciences (NASDAQ ALPN) News Headlines
|Zacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per Share|
www.americanbankingnews.com - February 13 at 5:24 AM
|Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by Analysts|
www.americanbankingnews.com - January 30 at 5:18 PM
|Alpine Immune Sciences (ALPN) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - January 16 at 4:36 PM
|Alpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - January 15 at 5:50 PM
|Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research|
www.americanbankingnews.com - January 4 at 5:52 PM
|Alpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 2 at 6:46 PM
|ValuEngine Upgrades Alpine Immune Sciences (ALPN) to Sell|
www.americanbankingnews.com - December 31 at 12:46 AM
|Alpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to Buy|
www.americanbankingnews.com - December 26 at 5:29 PM
|Zacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPS|
www.americanbankingnews.com - December 24 at 7:16 PM
|Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease|
finance.yahoo.com - December 19 at 8:55 AM
|Alpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - December 11 at 6:28 PM
|Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells|
finance.yahoo.com - December 6 at 9:05 AM
|Nivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - November 16 at 3:50 PM
|Nivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 15 at 5:06 PM
|Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results|
finance.yahoo.com - November 14 at 2:50 AM
|Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting|
finance.yahoo.com - November 10 at 2:28 PM
|Nivalis Therapeutics (ALPN) & The Competition Critical Review|
www.americanbankingnews.com - November 7 at 5:34 AM
|Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation|
finance.yahoo.com - November 6 at 4:34 PM
|Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November|
finance.yahoo.com - November 1 at 4:12 PM
|Zacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong Sell|
www.americanbankingnews.com - October 26 at 7:24 PM
|Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs|
finance.yahoo.com - October 23 at 4:51 PM
|Nivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - October 22 at 4:44 PM
|Alpine Immune Sciences Announces Upcoming Scientific Presentations|
finance.yahoo.com - October 16 at 4:35 PM
|Impel NeuroPharma names CEO|
www.bizjournals.com - October 6 at 4:21 AM
|Nivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel Nicolaus|
www.americanbankingnews.com - September 22 at 7:44 AM
|Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting|
finance.yahoo.com - September 20 at 3:41 PM
|Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference|
finance.yahoo.com - September 13 at 4:51 PM
|Nivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - September 2 at 7:16 PM
|-$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter|
www.americanbankingnews.com - August 15 at 6:06 PM
|Strength Seen in FibroGen (FGEN): Stock Soars 48.2%|
finance.yahoo.com - August 9 at 3:55 PM
|Nivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - August 8 at 6:44 PM
|Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session|
finance.yahoo.com - August 3 at 4:45 PM
|Alpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial Services|
www.americanbankingnews.com - July 27 at 9:24 AM
Alpine Immune Sciences (NASDAQ:ALPN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alpine Immune Sciences (NASDAQ:ALPN) Income Statement, Balance Sheet and Cash Flow Statement
Alpine Immune Sciences (NASDAQ ALPN) Stock Chart for Saturday, February, 17, 2018